Investors in CSL Ltd (ASX: CSL) have endured a tough year so far in 2025.
In August, shares in the healthcare titan tumbled by more than 21% after the company released its FY25 results.
In particular, an underperformance in its core plasma therapies business known as Berhing appeared to spook investors.
And another crunching blow followed this week.
On Tuesday, CSL shares dipped by 15% after it downgraded its earnings and revenue forecasts, whilst also halting plans to spin off its vaccines division.
Overall, shares in the company have now fallen by 36% since the start of the year to $179.56 per share at Thursday's close.
This compares with a solid 10% rise for the All Ordinaries Index (ASX: XAO) across the same period.
But where do CSL shares go from here?
Below we present the views of three portfolio managers from renowned Aussie investment firms, as reported in the Financial Review.
Image source: Getty Images
DNR Capital sees opportunity following sell down
Chief investment officer at DNR Capital, Jamie Nicol, believes that this week's sell-off was "disproportionate".
He also appeared to see the recent dip in CSL shares as a buying opportunity.
Nicol noted that the selldown was mainly related to CSL's flu business, which he considers to be a fairly small proportion of the company's overall value.
He commented:
There's been a big overreaction for something that's a small part of the business.
Adding that:
These are the sorts of opportunities you look for in markets.
Reportedly, CSL is one of DNR Capital's largest holdings.
Australian Ethical points to favourable valuation
Head of Australian equities at Australian Ethical Investment Ltd (ASX: AEF), Nathan Parkin, believes the fundamentals of the business remain sound, whilst recognising the market's reaction.
He commented:
It's been the second downgrade in a short period, but it doesn't really concern us in terms of the strength of Behring, the main business, which remains solid.
Meanwhile, this week's selldown appears to have created a valuation that Australian Ethical finds more favourable.
Parkin added:
Australian Ethical didn't hold CSL for more than a decade because they thought it was too expensive. Now we're seeing the flip side, the valuation looks appealing, and we think it's a good opportunity.
TenCap throws caution to the wind
However, portfolio manager at TenCap, Jun Bei Liu, appeared to take a more cautionary tone, stating:
For a growth company to start having those issues, it's really difficult to say to investors, 'trust me', when you have faltered so many times.
She added:
I wouldn't be surprised if management has to change as well when you disappoint that many times.
